Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

globenewswire.com
NVS Novartis' Zolgensma is mentioned as a significant revenue generator in the gene therapy market, indicating its importance but not providing specific forward-looking sentiment. SRPT Sarepta's Elevidys is highlighted for its revenue, positioning it as a key player, but the article doesn't offer explicit positive or negative outlook beyond its current financial contribution.

Ottawa, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The market for gene therapy and CRISPR-based therapeutics continues to grow rapidly, driven by breakthroughs in AAV-based therapies, ex vivo gene editing, and regenerative medicine. While some companies have started generating meaningful product revenue, others remain in clinical stages, funded through collaborations, cash reserves, and strategic acquisitions.

Invest in Our Premium Strategic Solution: https://www.precedenceresearch.com/request-consultation/42

Key Company Insights

The table below summarizes financial and operational highlights from major players in the gene therapy and CRISPR therapeutics sector:

Request Research Report Built Around Your Goals: sales@precedenceresearch.com

Government & Public Sector Initiatives

Governmental and regulatory bodies worldwide are actively supporting gene therapy research and commercialization. While direct spending is often embedded in broader health budgets, key initiatives include:

Market Trends & Insights

How Precedence Research Can Help

At Precedence Research, we provide in-depth, actionable insights that go beyond surface-level data:

Contact Us:

Email: sales@precedenceresearch.com

USA: +1 8044 419344 | APAC: +61 4859 81310 / +91 87933 22019 | Europe: +44 7383 092 044

Precedence Research – Turning Data Noise Into Strategic Clarity.